Altman Peter

BioCardia CEO Peter Altman buys 5,000 shares at depressed valuation amid company's sharp stock decline and ongoing losses.

Peter Altman, BioCardia's President and CEO, purchased 5,000 shares at a time when the stock is trading sharply below its highs following a steep recent decline. This is a meaningful signal of insider conviction—the company's CEO is putting his own capital at risk despite the stock's weakness and the company's fundamental challenges of unprofitable operations and contracting revenue. The trade is particularly noteworthy because Altman is buying into fundamental headwinds (the company remains deeply unprofitable with declining revenue trends), suggesting he believes the current depressed valuation offers a compelling entry point. For a CEO to accumulate shares in a loss-making biotech company during a downturn signals either that he sees a near-term catalyst or views the current price as a substantial discount to intrinsic value—both worth investigating further.

CEO Altman bought 1,000 shares at $1.23 (2 purchases, $1,230) as stock trades -61.8% from 52-week high

Peter Altman, President and CEO, made 2 separate purchases totaling 1,000 shares for $1,230.00 at a blended average price of $1.23 on April 20–21, 2026. The current stock price of $1.20 is now -61.8% from the 52-week high of $3.14, and the company is reporting zero revenue in the latest quarter with a net loss of $-1,483,000 and -100.0% annual revenue decline. His prior trades at BCDA show a 0% 90-day win rate (0 of 2 prior measurable buys produced positive 90-day returns), and his cross-ticker track record similarly shows a 17.65% 90-day win rate with an average 90-day return of -13.1%. The purchase occurs as the stock is trading near its 52-week lows and fundamentals remain severely distressed, but Altman's historical timing on both this ticker and across all his open-market buys suggests limited predictive value for near-term recovery.

BioCardia CEO Altman buys 900 shares in 2 transactions ($1.23 avg) amid -62.4% 52-week decline; same-ticker pattern shows 0 of 5 prior buys well-timed at 90d.

Peter Altman, President and CEO of BioCardia, purchased 900 shares across 2 separate transactions on 2026-03-24 and 2026-03-25 at a blended average price of $1.23, adding modestly to his 274.8K-share position. The company's fundamentals are severely stressed: latest-quarter revenue is $0.00, annual revenue has declined -100.0% year-over-year, and net income was $-1.5M with a market cap of only $12.9M. The stock is currently trading at $1.18, down -62.4% from its 52-week high of $3.14 and down -7.1% over the past 90 days. Against this backdrop, Altman's prior buy activity at BioCardia tells a cautionary story: of 5 prior recorded trades at this ticker, 0 of 2 measurable outcomes were well-timed at the 90-day mark, with his most recent prior buys (2026-01-20 and 2026-01-21) showing 90-day returns of -12.1% and -15.7% respectively. The current purchase arrives in the context of these repeated underperforming buy decisions at the same company.

CEO Peter Altman bought 5,000 BCDA shares at $1.13; 5th open-market purchase in 3 months as stock trades -65.3% from 52-week high.

Peter Altman, President and CEO, purchased 5,000 shares at $1.13 on 2026-02-04, his fifth discretionary open-market buy at BioCardia in the past three months. The stock has declined -65.3% from its 52-week high of $3.14 and currently trades at $1.09, below the transaction price. The company is unprofitable with net income of $-1,483,000 and annual revenue declined -87.8%, yet Altman continues to accumulate shares, increasing his holdings to 273.9K shares. His prior same-ticker buys show mixed results: the oldest measurable buy from 2025-09-19 returned +2.4% over 90 days, while recent purchases from late January 2026 remain outcome-indeterminate. The frequency of purchases during a steep decline and unprofitable operating environment warrants scrutiny of underlying circumstances.

BCDA CEO Peter Altman buys 900 shares at $1.33 avg (2 txns), now underwater on current $1.28 price; stock down 59.2% from 52-week high.

Peter Altman, President and CEO, purchased 900 shares across 2 transactions totaling $1,194.00 at a blended average price of $1.33 per share on 2026-01-20 and 2026-01-21. The current price of $1.28 is already below his transaction average and represents a 59.2% decline from the 52-week high of $3.14. At BioCardia specifically, Altman's prior 5 trades show a mixed record: only 1 of 3 prior buys measurable at the 90-day mark were well-timed (positive returns), while two earlier purchases delivered 90-day losses of -30.0% and -27.3%. The company's fundamentals are distressed—latest quarterly revenue is $0.00 with a net loss of $-1.5M, annual revenue growth declined 87.8%, and the market cap sits at $13.6M. His post-transaction holdings increased only 0.3% to 268.9K shares, a modest increase relative to the stock's volatility and the company's deteriorating financial position.

CEO Altman purchases 1,100 shares across 2 days at $1.31 blended average; stock down 59.6% from 52-week high

Peter Altman, President and CEO of BioCardia (BCDA), executed 2 separate purchases totaling 1,100 shares for $1,444.00 on December 16–17, 2025, at a blended average price of $1.31, raising his holdings to 268.0K shares. The company is unprofitable (net income -$1.5M in latest full year) with zero quarterly revenue and annual revenue growth of -87.8%, while the stock trades 59.6% below its 52-week high of $3.14. Altman's same-ticker history shows 5 prior buys at BCDA, with a timing pattern of 0 of 4 measurable outcomes well-timed at the 90-day mark (all four showed negative 90-day returns averaging -27.4%). His cross-ticker buy track record shows a 31.58% 90-day win rate and average 90-day return of -9.1%, suggesting a pattern of purchases that have not recovered materially in subsequent quarters.

CEO Altman buys 48.0K BCDA shares at $1.25; stock down 55.1% from 52-week high; 2 other insiders buying in 14-day cluster.

Peter Altman, President and CEO, purchased 48,000 shares at $1.25 on 2025-09-19, increasing his holdings by 28.4%. The company is in severe distress: revenue was $0.00 in the latest quarter, net income was $-2,049,000.00, and annual revenue growth contracted by -87.8%. The stock has declined 55.1% from its 52-week high of $3.14 and dropped 26.2% over the past 30 days. Across his prior trades at BCDA, Altman's timing has been inconsistent; his most recent buy on 2025-08-22 saw a 30-day loss of -36.6%, suggesting continued downward pressure. The filing reveals a cluster pattern: 2 other insiders also bought within the past 14 days, which may reflect an attempt to stabilize investor confidence, though the fundamental deterioration (zero revenue, expanding losses, severe revenue contraction year-over-year) raises questions about sustainability.

BCDA CEO Altman buys 700 shares at $1.83; stock down 51.5% from 52-week high, revenue fell 87.8% year-over-year, $-2.0M net income.

Peter Altman (President and CEO) purchased 700 shares at $1.83 on 2025-08-22, adding to a $1,281.00 total position. This represents a modest +0.4% increase to his 168.8K share holdings, consistent with recent buying activity at BCDA (three purchases within the prior 9 days). The timing coincides with significant fundamental headwinds: annual revenue declined 87.8%, the company reported a $-2.0M net income in its latest full fiscal year, and current trading sits at $1.95—down 51.5% from the 52-week high of $4.02 and 17.0% below levels 30 days prior. Across the insider's full cross-ticker history, his 20 prior buy transactions averaged a +12.6% 30-day return but only -0.2% at the 90-day mark with a 53.33% win rate, suggesting his individual buying decisions have not consistently preceded sustained stock appreciation.

CEO Altman buys 100 BCDA shares at $1.83 as stock trades -53.7% from 52-week high

Peter Altman, President and CEO, purchased 100 shares at $1.83 on 2025-08-13, bringing his holdings to 168,062 shares. This follows two additional purchases by Altman on 2025-08-12 and 2025-08-11, suggesting consecutive daily buying activity. The transaction occurs as BioCardia trades at $1.86, down 53.7% from its 52-week high and down 20.2% over the prior 30 days, while the company reports negative net income of $-2,049,000.00 and zero latest-quarter revenue against an 87.8% annual revenue decline. While Altman's cross-ticker buy track record shows a 69.23% 90-day win rate with +4.9% average return, his prior same-ticker history at BCDA shows mixed recent results: one prior buy returned +10.0% at 30 days, another returned -2.7%, and a June buy returned +5.5% (with no 90-day outcomes yet measurable).

BCDA CEO Altman buys 400 shares at $1.75 on 2025-08-12; stock -56.7% from 52-week high, revenue $0.00, $-2.0M net loss

Peter Altman, President and CEO, purchased 400 shares at $1.75 on 2025-08-12, adding to 167,962 total shares (168.0K shares) post-transaction. The purchase occurs in severely distressed context: the stock trades at $1.74, down -56.7% from its 52-week high of $4.02 and down -27.2% in the past 30 days. BioCardia's fundamentals are critically weak, with revenue of $0.00 in the latest quarter, a $-2.0M net loss, and annual revenue growth of -87.8%, indicating severe operational deterioration. While Altman's cross-ticker track record shows a 71.43% win rate on 20 prior buys with an average 90-day return of +6.5%, his same-ticker history at BCDA provides limited evidence of timing accuracy, with none of his five prior BCDA purchases yet showing 90-day measurable outcomes and the most recent prior buy occurring just one day earlier on 2025-08-11. The back-to-back daily purchases at declining prices suggest ongoing acquisition activity, but the magnitude of each transaction (400 shares) remains modest relative to the severe valuation deterioration and operational distress.